Issue: May 2023
Fact checked byHeather Biele

Read more

March 30, 2023
2 min read
Save

FDA limit on acetaminophen dosage linked to fewer hospitalizations, cases of liver failure

Issue: May 2023
Fact checked byHeather Biele
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • Limit in prescription and opioid products decreased yearly rate of hospitalizations (11%) and cases of acute liver failure (16%).
  • Researchers did not report the same reductions involving acetaminophen alone.
Perspective from William Carey, MD

A 2011 FDA mandate, which limited acetaminophen dosage to 325 mg/tablet in prescription acetaminophen and opioid products, correlated with a decrease in yearly hospitalizations and cases of acute liver failure related to toxicity.

“Anecdotally we had several patients in rapid succession with acetaminophen overdose — in the setting of taking over-the-counter flu/cold medications — requiring liver transplantation, and we wanted to understand FDA limits around dosing,” Jayme E. Locke, MD, MPH, FACS, FAST, director of the Comprehensive Transplant Institute at University of Alabama at Birmingham, told Healio. “Given the FDA mandate was restricted to prescription combination meds, we decided to see if cases of acute liver failure and hospitalizations were lower post- vs. pre-mandate.”

Following the FDA mandate, acetaminophen and opioid toxicity-related adverse outcomes decreased hospitalizations per year by 11%, and acute liver failure per year by 16%.
Data derived from: Orandi BJ, et al. JAMA. 2023;doi:10.1001/jama.2023.1080.

In an interrupted-series analysis published in JAMA, Locke and colleagues investigated the risk for hospitalization and the proportion of acute liver failure (ALF) cases related to acetaminophen and opioid toxicity before and after the FDA mandate; they derived data from the National Inpatient Sample (NIS) and the Acute Liver Failure Study Group (ALFSG).

Among 474,047,585 hospitalizations from 2007 to 2019 in NIS, 39,606 hospitalizations (median age, 42.2 years; 66.8% women) involved acetaminophen and opioid toxicity. From 1998 through 2019, there were 2,631 cases of ALF, of which 465 (median age, 39 years; 85.4% women) involved acetaminophen and opioid toxicity.

According to results, the predicted incidence of hospitalization 1 day before the FDA announcement was 12.2 cases per 100,000 hospitalizations (95% CI, 11.0-13.4), which dropped to 4.4 cases per 100,000 hospitalizations (95% CI, 4.1-4.7) by 2019.

The odds of acetaminophen and opioid toxicity-related hospitalizations increased 11% per year before the mandate (OR = 1.11; 95% CI, 1.06-1.15) and decreased by 11% per year after the mandate (OR = 0.89; 95% CI, 0.88-0.9).

Further, results showed the predicted percentage of ALF cases related to acetaminophen and opioid toxicity 1 day before the FDA announcement was 27.4% (95% CI; 23.3-31.9), which dropped to a predicted incidence of 5.3% (95% CI; 3.1-8.8) by 2019.

The proportion of ALF cases that involved acetaminophen and opioid toxicity increased to 7% per year before the announcement (OR = 1.07; 95% CI, 1.03-1.1) and decreased to 16% per year following the FDA mandate (OR = 0.84; 95% CI, 0.77-0.92).

“The FDA mandate resulted in fewer ALF cases and hospitalizations related to combination acetaminophen and opioid products,” Locke said. “We did not see the same reduction in acetaminophen alone cases, suggesting that it was the FDA mandate that had the biggest impact rather than education on the topic.”

Locke continued: “Next steps really need to focus on over-the-counter prescription products. The question remains should a similar mandate regarding acetaminophen dosing be in place for over-the-counter combination products as well. We need to be more aggressive about educating patients regarding the amount of acetaminophen in over-the-counter cold and flu medications and encourage patients not to combine these with additional doses of acetaminophen.”